Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1951

Sort by

Sort Order Select

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

The different flavors and splices of MCL

Oliver Weigert

Blood (2020) 136 (5): 526–527.

https://doi.org/10.1182/blood.2020005591

Published: 2020

Journal Articles

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Francisco Pedrosa, Elaine Coustan-Smith, Yinmei Zhou, Cheng Cheng, Arli Pedrosa, Mecneide Mendes Lins, Marcia Pedrosa, Norma Lucena-Silva, Alessandra Maria de Luna Ramos, Ester Vinhas, Gaston K. Rivera, Dario Campana, Raul C. Ribeiro

Blood (2020) 135 (17): 1458–1466.

https://doi.org/10.1182/blood.2019004215

Published: 2020

Includes: Supplemental data

Journal Articles

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Jessica C. Hochberg, MD, Jaclyn Basso, RN, MSN, PNP, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Allyson M. Flower, MD, Aliza Gardenswartz, MD, Qiuhu Shi, PhD, Perry Gerard, MD MBA, FACR, Humayan Islam, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 127.

https://doi.org/10.1182/blood-2019-128684

Published: 2019

Journal Articles

Longitudinal Trajectory of Frailty in Blood or Marrow Transplant (BMT) Survivors - a BMT Survivor Study (BMTSS)

Mukta Arora, MD, Yanjun Chen, MS, Jessica Wu, MPH, Lindsey Hageman, MPH, Emily Ness, MPH, Michelle Kung, MA, Liton F. Francisco, BS, Alysia Bosworth, BA, Daniel J. Weisdorf, MD, Stephen J Forman, MD, Wendy Landier, PhD CRNP, Merve - Pamukçuoğlu, MD, Saro H. Armenian, DO, MPH, Lennie Wong, PhD, Smita Bhatia, MDMPH

Blood (2019) 134 (Supplement_1): 699.

https://doi.org/10.1182/blood-2019-123344

Published: 2019

Journal Articles

Addition of Drug-Response Specific Micro-RNAs to the International Prognostic Index Improves Prognostic Stratification of GCB-DLBCL Patients Treated with R-CHOP

Karen Dybkær, PhD, Hanne Due, MSc, Rasmus Froberg Brøndum, PhD, Ken H. Young, MD PhD, Martin Bøgsted, PhD

Blood (2019) 134 (Supplement_1): 1623.

https://doi.org/10.1182/blood-2019-122351

Published: 2019

Journal Articles

Gene Polymorphisms and Vincristine-Induced Neuropathy in Patients Who Received R-CHOP Chemotherapy

Akihiko Sawaki, MD, Kana Miyazaki, MD PhD, Toshifumi Takeuchi, MD PhD, Kyoko Kobayashi, MD PhD, Hiroshi Imai, MD PhD, Isao Tawara, MD PhD, Ryoichi Ono, MD PhD, Tetsuya Nosaka, MD PhD, Motoko Yamaguchi, MD PhD, Naoyuki Katayama, MD PhD

Blood (2019) 134 (Supplement_1): 1624.

https://doi.org/10.1182/blood-2019-122796

Published: 2019

Journal Articles

BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Juan J. Gu, MD PhD, Michael Vacaro, Kris Attwood, PhD MS, Cory Mavis, MSc, Pallawi Torka, MD, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 1629.

https://doi.org/10.1182/blood-2019-128512

Published: 2019

Journal Articles

Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era

Blood (2019) 134 (Supplement_1): 1619.

https://doi.org/10.1182/blood-2019-131435

Published: 2019

Journal Articles

Survival Patterns in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: Treatment Trajectories and Responses after the First Relapse

Ahmad S Halwani, MD, Hsu-Chih Chien, PhD MSc, Deborah Kay Morreall, BS, Vikas Patil, MS, Kelli M Rasmussen, MS, Catherine Li, PhD, Zachary R Burningham, PhD, Anthony S Masaquel, PhD MPH, Mary Halloran, PharmD, BCPS, Elisha Delong-Sieg, PharmD, Mathias Schulz, MD MBA, Jia Li, PhD, Brian C Sauer, PhD

Blood (2019) 134 (Supplement_1): 1622.

https://doi.org/10.1182/blood-2019-127719

Published: 2019

Journal Articles

Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939

Martine Humbert, PhD, Armelle Goubard, PhD, Colin Mansfield, PhD, Olivier Hermine, MD PhD, Patrice Dubreuil, PhD, The AB8939 Study Group

Blood (2019) 134 (Supplement_1): 2075.

https://doi.org/10.1182/blood-2019-122540

Published: 2019

Journal Articles

Blocking Lysosomal Two-Pore Channel 2 Function Inhibits Proliferation of Multidrug Resistant Leukemia Cells and Sensitizes Them to Vincristine Treatment

Martin Müller, MSc, Franz Geisslinger, Susanne Gerndt, Ramona Schütz, Yu-Kai Chao, Franz Bracher, Christian Grimm, Angelika Vollmar, Karin Bartel

Blood (2019) 134 (Supplement_1): 2081.

https://doi.org/10.1182/blood-2019-128195

Published: 2019

Journal Articles

Real-World Treatment Patterns and Overall Survival Among Medicare Fee-for-Service Beneficiaries Newly Diagnosed with Peripheral T-Cell Lymphoma

Anne Shah, MS, Allison Petrilla, MPH, Mayvis Rebeira, PhD, Joseph Feliciano, PharmD, Thomas W. LeBlanc, MDMA,MHS, Julie Lisano, PharmD

Blood (2019) 134 (Supplement_1): 3492.

https://doi.org/10.1182/blood-2019-130973

Published: 2019

Journal Articles

Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R 2 -CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study

Blood (2019) 134 (Supplement_1): 3475.

https://doi.org/10.1182/blood-2019-123948

Published: 2019

Journal Articles

Utility of Daily Laboratories in Patients with Lymphoma Admitted for Inpatient Chemotherapy

Daniel Anscher, MD, Ahmad El-Far, MD, Said M Baidas

Blood (2019) 134 (Supplement_1): 3417.

https://doi.org/10.1182/blood-2019-121558

Published: 2019

Journal Articles

Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphoma Patients Receiving First-Line Treatment in Routine Clinical Practice in France and the United Kingdom

Christopher P Fox, MBChB(Hons), MRCP, FRCPath, PhD, Ajibade O Ashaye, MD MBA, MPH, MSc., Ruchit Shah, PhD, Shelby Corman, PharmD, MS, BCPS, Mehul Dalal, PhD, Lorenz Truemper, MD

Blood (2019) 134 (Supplement_1): 3482.

https://doi.org/10.1182/blood-2019-127289

Published: 2019

Journal Articles

Health Resource Utilization and Costs Associated with the Use of Obinutuzumab-Based Regimens Are Similar to Rituximab-Based Regimens for the First-Line Treatment of Follicular Lymphoma

Tu My To, PhD, Keith L. Dawson, DNP, MS, Anthony S Masaquel, PhD MPH, Arpamas Seetasith, PhD

Blood (2019) 134 (Supplement_1): 4721.

https://doi.org/10.1182/blood-2019-123408

Published: 2019

Journal Articles

Fas Mutations in Non-Hodgkin's Lymphoma (NHL): Implications for Disease Progression and Therapeutic Resistance

Ryan N Rys, BSc, BA, Maanasa Venkataraman, MSc, Jibin Zeng, MSc, Koren Kathleen Mann, PhD, Nathalie Johnson, MD

Blood (2019) 134 (Supplement_1): 1520.

https://doi.org/10.1182/blood-2019-130602

Published: 2019

Journal Articles

CEOP/IVE/GDP Alternating Regimen Compared with CEOP As the First-Line Therapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma: Results from a Phase 2, Multi-Center, Randomized, Controlled Clinical Trial

Mingci Cai, MD, Shu Cheng, MD PhD, Wang Xin, PhD, Jianda Hu, PhD, Yongping Song, Zixun Yan, Yujie Jiang, MD, Xiaosheng Fang, PhD, Xiaoyun Zheng, Lihua Dong, Mengmeng Ji, Li Wang, MD PhD, Pengpeng Xu, Weili Zhao

Blood (2019) 134 (Supplement_1): 1556.

https://doi.org/10.1182/blood-2019-122369

Published: 2019

Journal Articles

Vincristine-Induced Peripheral Neuropathy in Pediatric Oncology Patients Receiving Vincristine through Push Injections or One-Hour Infusions: Results of a Randomized Clinical Trial

Mirjam Esther Van De Velde, MD, Gertjan Johannes Laurentius Kaspers, Prof. MD PhD, Floor Abbink, MD, Marry M. van den Heuvel-Eibrink, Prof, MD PhD, Cor van den Bos, MD PhD, Inge M. van der Sluis, MD PhD, Heidi Segers, MD PhD, Leen Willems, MD PhD, Jutte Van Der Werff, Prof, MD PhD, Christophe Chantrain, MD PhD, Machteld Heleen van den Berg, PhD

Blood (2019) 134 (Supplement_1): 1350.

https://doi.org/10.1182/blood-2019-126532

Published: 2019

NARROW

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

The different flavors and splices of MCL

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Longitudinal Trajectory of Frailty in Blood or Marrow Transplant (BMT) Survivors - a BMT Survivor Study (BMTSS)

Addition of Drug-Response Specific Micro-RNAs to the International Prognostic Index Improves Prognostic Stratification of GCB-DLBCL Patients Treated with R-CHOP

Gene Polymorphisms and Vincristine-Induced Neuropathy in Patients Who Received R-CHOP Chemotherapy

BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era

Survival Patterns in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: Treatment Trajectories and Responses after the First Relapse

Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939

Blocking Lysosomal Two-Pore Channel 2 Function Inhibits Proliferation of Multidrug Resistant Leukemia Cells and Sensitizes Them to Vincristine Treatment

Real-World Treatment Patterns and Overall Survival Among Medicare Fee-for-Service Beneficiaries Newly Diagnosed with Peripheral T-Cell Lymphoma

Utility of Daily Laboratories in Patients with Lymphoma Admitted for Inpatient Chemotherapy

Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphoma Patients Receiving First-Line Treatment in Routine Clinical Practice in France and the United Kingdom

Health Resource Utilization and Costs Associated with the Use of Obinutuzumab-Based Regimens Are Similar to Rituximab-Based Regimens for the First-Line Treatment of Follicular Lymphoma

Fas Mutations in Non-Hodgkin's Lymphoma (NHL): Implications for Disease Progression and Therapeutic Resistance

CEOP/IVE/GDP Alternating Regimen Compared with CEOP As the First-Line Therapy for Newly Diagnosed Patients with Peripheral T-Cell Lymphoma: Results from a Phase 2, Multi-Center, Randomized, Controlled Clinical Trial

Vincristine-Induced Peripheral Neuropathy in Pediatric Oncology Patients Receiving Vincristine through Push Injections or One-Hour Infusions: Results of a Randomized Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only